Hims & Hers Health (HIMS) Income from Continuing Operations (2019 - 2026)
Hims & Hers Health (HIMS) reported Income from Continuing Operations of 92115000.0 for Q1 2026, down 286.15% on a YoY basis from 49485000.0 in Q1 2025, and down 547.14% sequentially from 20601000.0 in Q4 2025.
Hims & Hers Health (HIMS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Income from Continuing Operations data on file, last reported at 92115000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 286.15% year-over-year to 92115000.0; the trailing twelve-month figure through Mar 2026 stood at 13235000.0 (down 108.05% YoY), and the FY2025 full-year result was 128365000.0, up 1.85% from the prior year.
- Income from Continuing Operations retreated to 92115000.0 in Q1 2026, from 20601000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 75588000.0 in Q3 2024 to a low of 92115000.0 in Q1 2026.
- A 5-year average of 4297882.35 and a median of 1245000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 1990.36% in 2024 and slumped 286.15% in 2026, its largest moves.
- Tracing HIMS's Income from Continuing Operations over 5 years: stood at 10907000.0 in 2022, then surged by 111.41% to 1245000.0 in 2023, then soared by 1990.36% to 26025000.0 in 2024, then dropped by 20.84% to 20601000.0 in 2025, then slumped by 547.14% to 92115000.0 in 2026.
- Business Quant data shows HIMS's Income from Continuing Operations at 92115000.0 in Q1 2026, 20601000.0 in Q4 2025, and 15774000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | -92.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.12 Mn |
| Dec 31, 2025 | 20.60 Mn |
| Sep 30, 2025 | 15.77 Mn |
| Jun 30, 2025 | 42.51 Mn |
| Mar 31, 2025 | 49.49 Mn |
| Dec 31, 2024 | 26.03 Mn |
| Sep 30, 2024 | 75.59 Mn |
| Jun 30, 2024 | 13.30 Mn |
| Mar 31, 2024 | 11.13 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | -7.57 Mn |
| Jun 30, 2023 | -7.16 Mn |
| Mar 31, 2023 | -10.07 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -18.84 Mn |
| Jun 30, 2022 | -19.68 Mn |
| Mar 31, 2022 | -16.25 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -15.94 Mn |
| Jun 30, 2021 | -9.15 Mn |